Bristol-Myers Squibb Company (BMY)
Cash ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 10,346,000 | 7,890,000 | 6,293,000 | 9,330,000 | 11,464,000 | 7,514,000 | 8,372,000 | 8,995,000 | 9,123,000 | 7,734,000 | 10,750,000 | 12,369,000 | 13,979,000 | 13,540,000 | 11,024,000 | 10,982,000 | 14,546,000 | 19,435,000 | 19,934,000 | 15,817,000 |
| Short-term investments | US$ in thousands | 802,000 | 892,000 | 953,000 | 902,000 | 1,275,000 | 517,000 | 1,206,000 | 1,181,000 | 1,234,000 | 2,212,000 | 3,531,000 | 4,053,000 | 5,006,000 | 6,001,000 | 5,360,000 | 5,204,000 | 4,737,000 | 4,781,000 | 4,576,000 | 4,472,000 |
| Total current liabilities | US$ in thousands | 23,774,000 | 22,638,000 | 23,265,000 | 25,822,000 | 22,262,000 | 23,462,000 | 20,150,000 | 19,085,000 | 21,890,000 | 18,930,000 | 20,915,000 | 22,821,000 | 21,868,000 | 21,460,000 | 18,991,000 | 17,330,000 | 19,080,000 | 20,464,000 | 23,421,000 | 19,232,000 |
| Cash ratio | 0.47 | 0.39 | 0.31 | 0.40 | 0.57 | 0.34 | 0.48 | 0.53 | 0.47 | 0.53 | 0.68 | 0.72 | 0.87 | 0.91 | 0.86 | 0.93 | 1.01 | 1.18 | 1.05 | 1.05 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($10,346,000K
+ $802,000K)
÷ $23,774,000K
= 0.47
The cash ratio of Bristol-Myers Squibb Company has exhibited a declining trend from 1.05 as of March 31, 2020, to 0.47 as of December 31, 2024. This ratio indicates the company's ability to cover its short-term obligations with its cash and cash equivalents.
Throughout the analyzed period, the cash ratio remained above 1, indicating that Bristol-Myers Squibb had more than enough cash on hand to cover its current liabilities. However, the decreasing trend in the cash ratio suggests that the company may have become less liquid over time, potentially indicating a reduction in the availability of liquid assets relative to its current liabilities.
It is important to note that a cash ratio below 1 implies that the company may not have enough cash to cover its short-term obligations, potentially raising concerns about liquidity and the ability to meet immediate financial obligations. As such, monitoring the trend of the cash ratio over time is crucial for assessing Bristol-Myers Squibb's liquidity position.
Peer comparison
Dec 31, 2024